Two Ways: Ask Your Doctor About Merck and Schering-Plough
Strengthen your portfolio in good times and bad.
Side Effects Include...
Merck (MRK) has joined forces with Schering-Plough (SGP) in a deal worth $41.1 billion. It's a cash-and-stock transaction in which Schering-Plough shareholders will receive a premium of 34% to Friday's closing price. In a statement, Chairman and CEO Richard T. Clark said, "The combined company will benefit from a formidable pipeline, a significantly broader portfolio of medicines, and an expanded presence in key international markets."
Toddo mentioned a few of these Big Pharma plays last week in Freaky Friday Potpourri.
From the Bull Pen: Those bullish can look to the Biotech HOLDRS Trust (BBH). A sell stop can be set 2% below entry.
From the Bear Cave: Professor Quint Tatro has got Gilead Sciences (GILD) on the radar. It shows resistance on the weekly chart near $50. One can initiate a downside position if and when it rallies to that level.
Quick Check Around the World
Asian trading closed with the Hang Seng -4.84%, Nikkei -1.21%, India -1.99%, Taiwan -0.55% and Shanghai -3.39.
Glancing towards Europe, we see the CAC -1.55%, DAX -1.12%, FTSE -1.43%
As of 8:05 AM EST, S&P Futures are trading -10 to 677, and Nasdaq futures are -12 to 1064.
A Look At Commodities
Crude oil is trading +0.32 to 45.84. Gold is -5.10 to 937.60. Silver is +1.70 to 13.350, and copper -4.40 to 164.50.
The dollar index is +0.6750to 89.2250.
Not much on the radar today but click here to see the full list of this week's events.
Happy Monday! Good luck, Minyans!
Actionable ideas, instant analysis. Real-time from bell to bell.
Minyanville's Buzz & Banter - 14 day FREE trial
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.
Copyright 2011 Minyanville Media, Inc. All Rights Reserved.
Daily Recap Newsletter